Clinical Trial Update: A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is assessing SHR-A2009 in combination with Aumolertinib versus Aumolertinib alone as first-line therapy for EGFR-mutated, advanced or m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Aumolertinib (Aumolertinib)
• SHR-A2009

Snippet

Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: RECRUITING